{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:30:36Z","timestamp":1793035836117,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejim.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T01:04:54Z","timestamp":1579050294000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Management of hyperuricemia in asymptomatic patients: A critical appraisal"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-5600","authenticated-orcid":false,"given":"Antonio","family":"Brucato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-196X","authenticated-orcid":false,"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.01.001_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"10.1016\/j.ejim.2020.01.001_bib0002","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.molbev.a004123","article-title":"Loss of urate oxidase activity in hominoids and its evolutionary implications","volume":"19","author":"Oda","year":"2002","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.ejim.2020.01.001_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semnephrol.2004.09.002","article-title":"Uric acid, evolution and primitive cultures. In: uric acid in cardiovascular and renal disease","volume":"25","author":"Johnson","year":"2005","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ejim.2020.01.001_bib0004","first-page":"23","article-title":"Gout, genetics and ABC transporters","volume":"3","author":"Basseville","year":"2011"},{"key":"10.1016\/j.ejim.2020.01.001_bib0005","first-page":"3","article-title":"Gout and hyperuricemia","volume":"36","author":"Chilappa","year":"2010","journal-title":"Compr Ther"},{"issue":"4","key":"10.1016\/j.ejim.2020.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","article-title":"Uric acid as a CNS antioxidant gene L","volume":"19","author":"Bowman","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11357-016-9871-8","article-title":"Serum uric acid level and association with cognitive impairment and dementia: Systematic review and meta-analysis","volume":"38","author":"Khan","year":"2016","journal-title":"Age"},{"key":"10.1016\/j.ejim.2020.01.001_bib0008","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s12035-015-9271-6","article-title":"Inverse association between serum uric acid levels and Alzheimer's disease risk","volume":"53","author":"Du","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejim.2020.01.001_bib0009","first-page":"e88","article-title":"Uric acid: neuroprotective or neurotoxic?","volume":"39","author":"Proctor","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2020.01.001_bib0010","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1038\/srep14325","article-title":"Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2020.01.001_bib0011","doi-asserted-by":"crossref","unstructured":"Bardin T, Richette P.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options BMC Med, 15 (2017), p. 123.","DOI":"10.1186\/s12916-017-0890-9"},{"key":"10.1016\/j.ejim.2020.01.001_bib0012","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"88","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2020.01.001_bib0013","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricaemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2020.01.001_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nature Reviews Rheumatology"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2012.12.034","article-title":"Association of serum uric acid and cardiovascular disease in healthy adults","volume":"111","author":"Kivity","year":"2013","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.ejim.2020.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0017","first-page":"e14525","article-title":"Prognostic value of serum uric acid in patients with acute heart failure","volume":"98","author":"Huang","year":"2019","journal-title":"A meta-analysis. Medicine"},{"issue":"15","key":"10.1016\/j.ejim.2020.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.01.001_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2261-13-115","article-title":"Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Troms\u00f8 Study","volume":"13","author":"Storhaug","year":"2013","journal-title":"BMC Cardiovascular Disorders"},{"key":"10.1016\/j.ejim.2020.01.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0023-2019","article-title":"Screening for pulmonary arterial hypertension in systemic sclerosis","volume":"28","author":"Weatherald","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ejim.2020.01.001_bib0021","doi-asserted-by":"crossref","unstructured":"Reynolds T. Serum uric acid, the endothelium and hypertension: an association revisited. Hum Hypertens. 007;21(8):591.","DOI":"10.1038\/sj.jhh.1002239"},{"key":"10.1016\/j.ejim.2020.01.001_bib0022","doi-asserted-by":"crossref","first-page":"f4262","DOI":"10.1136\/bmj.f4262","article-title":"Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts","volume":"347","author":"Palmer","year":"2013","journal-title":"BMJ"},{"issue":"344","key":"10.1016\/j.ejim.2020.01.001_bib0023","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"12","author":"Choi","year":"2012","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ejim.2020.01.001_bib0024","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/annrheumdis-2012-202589","article-title":"Low-dose aspirin use and recurrent gout attacks","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0026","series-title":"Gout & other crystal arthropathies","article-title":"Overview of gout therapy strategy and targets, and the management of refractory disease","author":"Liot\u00e9","year":"2012"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0027","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR Decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, Placebo-Controlled Trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s10157-015-1095-1","article-title":"Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial","volume":"19","author":"Tanaka","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2020.01.001_bib0029","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cen.12673","article-title":"Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study","volume":"83","author":"Liu","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ejim.2020.01.001_bib0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0031","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ejim.2020.01.001_bib0032","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0033","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ejim.2020.01.001_bib0034","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2016050521","article-title":"Vascular Function and Uric Acid-Lowering in Stage 3 CKD","volume":"28","author":"Jalal","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"10.1016\/j.ejim.2020.01.001_bib0035","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2169\/internalmedicine.54.4310","article-title":"The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study","volume":"54","author":"Liu","year":"2015","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0036","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","article-title":"Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia","volume":"63","author":"Takir","year":"2015","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejim.2020.01.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/2054358116675343","article-title":"A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy","volume":"3","author":"Beddhu","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0038","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0039","first-page":"563","article-title":"Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial","volume":"17","author":"Mukri","year":"2018","journal-title":"Excli j"},{"issue":"3","key":"10.1016\/j.ejim.2020.01.001_bib0040","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.4088\/JCP.15f09870","article-title":"The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ejim.2020.01.001_bib0041","unstructured":"Higgins JPT, Sterne JAC, Savovi\u0107 J, Page MJ, Hr\u00f3bjartsson A, Boutron I, et\u00a0al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V(editors). Cochrane Methods. Cochrane Database of Systematic Reviews2016, Issue 10 (Suppl 1)."},{"issue":"11","key":"10.1016\/j.ejim.2020.01.001_bib0042","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.recesp.2016.07.029","article-title":"New oral hypoglycemic agents and cardiovascular risk. Crossing the metabolic border","volume":"69","author":"Dalama","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"7","key":"10.1016\/j.ejim.2020.01.001_bib0043","first-page":"41","article-title":"Effect of metformin on the clinical course of gout and insulin resistance","volume":"87","author":"Barskova","year":"2009","journal-title":"Klin Med (Mosk)"},{"issue":"2","key":"10.1016\/j.ejim.2020.01.001_bib0044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.31887\/DCNS.2011.13.2\/npatsopoulos","article-title":"A pragmatic view on pragmatic trials","volume":"13","author":"Patsopoulos","year":"2011","journal-title":"Dialogues Clin Neurosci"},{"issue":"11","key":"10.1016\/j.ejim.2020.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/nep.13177","article-title":"Renoprotective effects of topiroxostat for hyperuremic patients with overt diabetic nephropathy study (ETUDE Study): A prospective, randomized, multicenter clinical trial","volume":"23","author":"Mizukoshi","year":"2018","journal-title":"Nephrology"},{"issue":"3","key":"10.1016\/j.ejim.2020.01.001_bib0046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MAJ.0b013e31815acb10","article-title":"Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy","volume":"335","author":"Chung","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ejim.2020.01.001_bib0047","first-page":"145","article-title":"New and improved strategies for the treatment of gout","volume":"3","author":"Dubchak","year":"2010","journal-title":"Int J Nephrol Renovasc"},{"issue":"4","key":"10.1016\/j.ejim.2020.01.001_bib0048","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0049","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0090-9556(25)06638-3","article-title":"Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites","volume":"23","author":"He","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.ejim.2020.01.001_bib0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9629(15)40340-4","article-title":"Acute renal failure due to sulfinpyrazone","volume":"315","author":"Walls","year":"1998","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.ejim.2020.01.001_bib0051","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpdd.323","article-title":"Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment","volume":"6","author":"Shen","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.ejim.2020.01.001_bib0052","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2020.01.001_bib0053","first-page":"1","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two Phase II trials","volume":"18","author":"Fitz-Patrick","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0054","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2020.01.001_bib0055","doi-asserted-by":"crossref","first-page":"e00291","DOI":"10.1002\/prp2.291","article-title":"Uricosuric targets of tranilast","volume":"5","author":"Mandal","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ejim.2020.01.001_bib0056","series-title":"Uloric (febuxostat): drug safety communication - FDA to evaluate increased risk of heart-related death","year":"2018"},{"issue":"13","key":"10.1016\/j.ejim.2020.01.001_bib0057","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout, Gunawardhana L; CARES investigators","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2020.01.001_bib0058","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14656566.2018.1498842","article-title":"Febuxostat for the treatment of hyperuricaemia in gout","volume":"19","author":"Robinson","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.ejim.2020.01.001_bib0059","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.numecd.2019.06.016","article-title":"The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0060","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases,1950\u20132012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejim.2020.01.001_bib0061","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2020.01.001_bib0062","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00000441-198610000-00006","article-title":"Evaluation of a thiazide-allopurinol drug interaction","volume":"292","author":"Hande","year":"1986","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.ejim.2020.01.001_bib0063","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejim.2020.01.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.190339","article-title":"Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population\u2013based cohort study","volume":"191","author":"Yokose","year":"2019","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.ejim.2020.01.001_bib0065","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthr Care & Res"},{"key":"10.1016\/j.ejim.2020.01.001_bib0066","first-page":"1","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"0","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2020.01.001_bib0067","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2796.1990.tb00195.x","article-title":"Azathioprine and allopurinol: a potentially dangerous combination","volume":"228","author":"Venkat Raman","year":"1990","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.ejim.2020.01.001_bib0068","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/106002809603000906","article-title":"Azathioprine and allopurinol: the price of an avoidable drug interaction","volume":"30","author":"Kennedy","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2020.01.001_bib0069","unstructured":"Allopurinol oral tablets (package insert). Memphis, TN: Northstar Rx LLC; 2015."},{"issue":"2","key":"10.1016\/j.ejim.2020.01.001_bib0070","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000489145","article-title":"Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound","volume":"43","author":"Viggiano","year":"2018","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.ejim.2020.01.001_bib0071","unstructured":"https:\/\/www.rheumatology.org\/Portals\/0\/Files\/Gout-Guideline-Project-Plan.pdf."},{"key":"10.1016\/j.ejim.2020.01.001_bib0072","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken) 2012"},{"key":"10.1016\/j.ejim.2020.01.001_bib0073","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1185\/03007995.2015.1087982","article-title":"The management of hyperuricemia with urate deposition","volume":"31","author":"Desideri","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2020.01.001_bib0074","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British society for rheumatology and british health professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2020.01.001_bib0076","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.01.001_bib0077","unstructured":"Management of initial gout in adults. The University of Texas at Austin, school of nursing, family nurse practitioner program. Available:http:\/\/www.alabmed.com\/uploadfile\/2014\/0515\/20140515070230703.pdf."},{"key":"10.1016\/j.ejim.2020.01.001_bib0078","series-title":"Rheumatology","author":"Hochberg","year":"2015"},{"key":"10.1016\/j.ejim.2020.01.001_bib0079","series-title":"Harrison","author":"Fauci","year":"2009"},{"key":"10.1016\/j.ejim.2020.01.001_bib0080","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"5","key":"10.1016\/j.ejim.2020.01.001_bib0081","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5603\/CJ.2018.0116","article-title":"Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk","volume":"25","author":"Borghi","year":"2018","journal-title":"Cardiol J"},{"issue":"8","key":"10.1016\/j.ejim.2020.01.001_bib0082","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3949\/ccjm.69.8.594","article-title":"Asymptomatic hyperuricemia: to treat or not to treat","volume":"69","author":"Dincer","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ejim.2020.01.001_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026677","article-title":"Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2020.01.001_bib0084","first-page":"241","article-title":"The diagnosis and treatment advice of cardiovascular disease combined asymptomatic hyperuricemia (second edition)","volume":"10","author":"Hu","year":"2012","journal-title":"Chin J Cardiovas Res"},{"key":"10.1016\/j.ejim.2020.01.001_bib0085","first-page":"158","article-title":"Portuguese recommendations for the diagnosis and management of gout","volume":"39","author":"Ara\u00fajo","year":"2014","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"10.1016\/j.ejim.2020.01.001_bib0086","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy","year":"2014","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ejim.2020.01.001_bib0087","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archinte.1974.00320150023002","article-title":"Hyperuricemic acute renal failure","volume":"133","author":"Kjellstrand","year":"1974","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.ejim.2020.01.001_bib0088","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM198611273152204","article-title":"Randomized trial of allopurinol in the prevention of calcium oxalate calculi","volume":"315","author":"Ettinger","year":"1986","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2020.01.001_bib0089","first-page":"101","article-title":"Prevention and management of tumor lysis syndrome in adults with malignancy","volume":"4","author":"Sarno","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ejim.2020.01.001_bib0090","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Mitchell","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ejim.2020.01.001_bib0091","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamainternmed.2014.1427","article-title":"Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment","volume":"174","author":"Carnovale","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ejim.2020.01.001_bib0092","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jbspin.2014.02.012","article-title":"Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines","volume":"81","author":"Banse","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2020.01.001_bib0093","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00228-014-1752-4","article-title":"Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry","volume":"70","author":"Pasina","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejim.2020.01.001_bib0094","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jama.294.6.716","article-title":"Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance","volume":"294","author":"Boyd","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.01.001_bib0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40266-014-0163-7","article-title":"Medication non-adherence among elderly patients newly discharged and receiving polypharmacy","volume":"31","author":"Pasina","year":"2014","journal-title":"Drugs Aging"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:31:45Z","timestamp":1760607105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520300017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":95,"alternative-id":["S0953620520300017"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.01.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hyperuricemia in asymptomatic patients: A critical appraisal","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}